A pediatric ALL patient survey including BCR/ABL1 patients who received imatinib therapy, identified enhanced MYB regulation by alternative MYB promoters in relapsed/therapy-resistant patients, which was accompanied by enhanced KRAS signaling, increased ABC transporter expression (ABCA2, ABCB5, ABCC10) and elevated drug degradation enzyme levels (CYP1A2, CYP2C9, CYP3A5)[131]. Here, MYB is linked to acute lymphoblastic leukemia.